Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Roy Baynes filed a Form 144 proposing to sell 9,750 shares of Common Stock via a stock option exercise on 05/01/2026 for cash, through Morgan Stanley Smith Barney LLC. The form also discloses two prior sales in the past three months: 32,750 shares on 04/14/2026 for $1,352,130 and 10,000 shares on 04/06/2026 for $330,000.
Travere Therapeutics ownership disclosure: Vanguard Capital Management reports beneficial ownership of 4,699,424 shares of Common Stock, representing 5.09% of the class as reported for the period ending 03/31/2026. The filing shows sole voting power over 653,612 shares and sole dispositive power over 4,699,424 shares. The disclosure states these holdings are exercised across Vanguard affiliates and include securities held for client accounts and Vanguard funds.
Travere Therapeutics, Inc. Chief Research Officer William E. Rote reported an open-market sale of 9,100 shares of common stock at $39.09 per share. After this transaction, he directly holds 113,987 shares. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan and includes shares sold to cover tax obligations from vesting performance restricted stock units.
William E. Rote submitted a Form 144 notice reporting proposed sale of 9,100 shares of Common Stock tied to restricted stock vesting on 04/13/2026. The filing also records that 12,446 shares were sold on 02/03/2026 for $409,100.02. The securities are listed on NASDAQ.
Travere Therapeutics director Gary A. Lyons exercised stock options and sold shares on the same day. He exercised options for 8,000 shares of Common Stock at an exercise price of $16.3300 per share, then sold 8,000 shares at $41.0700 per share.
The sale was carried out under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 11, 2025, and involved shares underlying options expiring on May 18, 2026. Following these transactions, he directly holds 57,500 shares of Travere Therapeutics Common Stock.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold shares in a planned transaction. He exercised options covering 32,750 shares of common stock at exercise prices between $15.43 and $21.38 per share, then sold 32,750 shares in open-market trades at $41.07 and $42.12 per share under a Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, he directly owned 37,500 shares of Travere Therapeutics common stock.
Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin reported an option exercise and share sale. On April 14, 2026, she exercised employee stock options covering 15,250 shares of common stock at exercise prices of $22.40, $8.93, and $20.46 per share. She then sold 21,977 shares of common stock at $41.07 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After these transactions, she directly held 42,353 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. chief commercial officer Peter Heerma reported a grant of 14,000 shares of common stock and a related share sale. The 14,000-share award on April 13, 2026 reflects settlement of performance restricted stock units tied to FDA approval of FILSPARI in FSGS. On April 14, 2026, he sold 7,215 shares at an average price of $41.9288 solely to cover tax withholding on the vested units under the company’s equity incentive plan. Following these transactions, he directly holds 138,608 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported receiving 14,000 shares of common stock as an equity award. The shares were acquired at no cost and are tied to performance restricted stock units granted on January 31, 2025.
According to the disclosure, these PSUs vested on April 13, 2026 after Travere confirmed that the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS. Following this vesting and share issuance, Rote directly holds 123,087 shares of Travere Therapeutics common stock, reflecting both this award and his existing stake.
Travere Therapeutics, Inc. director and CEO Eric M. Dube reported a PSU vesting and related share sales. On April 13, 2026, he acquired 64,000 shares of common stock at no cost through vested performance restricted stock units, triggered by FDA approval of FILSPARI (sparsentan) in FSGS.
On April 15, 2026, he sold 56,815 shares at a weighted average price of $41.01, 7,165 shares at a weighted average price of $41.75, and 20 shares at $42.66, all in open-market transactions under a Rule 10b5-1 trading plan that also covered tax obligations from the PSU vesting. Following these transactions, he directly holds 432,886 shares of Travere common stock, the same level as before the grant and sales.